TIDMMEDG 
 
RNS Number : 8121G 
Medgenics Inc 
08 February 2010 
 

                                Medgenics, Inc. 
                         ('Medgenics' or the 'Company') 
 
                                Issue of Equity 
 
8 February 2010 
 
 
The Company announces that, pursuant to an agreement between the Company and 
Equity Source Partners, LLC ("ESP") dated 1 May 2009, on 19 January 2010 a Board 
resolution was passed to issue and allot 1,275,000 common US $0.0001 shares in 
the Company ("Common Shares") conditional upon admission to trading on AIM. The 
Common Shares were issued as compensation for services rendered to the Company 
by ESP.  Application has now been made to the London Stock Exchange for the new 
Common Shares to be admitted to trading on AIM. Dealings are expected to 
commence at 8.00 a.m. on 9 February 2010. 
Following the admission to trading of the new Common Shares, the Company's total 
issued share capital will be 123,449,027* Common Shares and the percentage of 
AIM Securities not in public hands will be 28.9%*. 
 
Note 
* Excluding any Common Shares issued pursuant to the block admission between 4 
December 2009 and the date of this announcement and the 192,591 new Common 
Shares which certain directors of the Company irrevocably agreed to subscribe 
for on 5 February 2010. 
 
For further information, contact: 
 
Medgenics, Inc.                              +972 4 902 8900 
Dr. Andrew L. Pearlman 
 
De Facto Communications                      +44 20 7861 3838 
Mike Wort                                    m.wort@defacto.com 
Anna Dunphy a.dunphy@defacto.com 
 
Grayling (Investor Relations - US)           +1 646 284 9472 
Leslie Wolf-Creutzfeldt                      lwolf-creutzfeldt@hfgcg.com 
Blomfield Corporate Finance (Nomad)          +44 207 444 0800 
James Pinner 
Alan MacKenzie 
 
SVS Securities plc (Broker)                  +44 207 638 5600 
Peter Manfield 
 
About Medgenics: 
Medgenics is a clinical-stage biopharmaceutical company developing its unique 
tissue-based Biopump platform technology to provide sustained-action protein 
therapy for the treatment of a range of chronic diseases. The Company currently 
has three products in development based on this technology and addressing the 
indications of: 
 
 - Anaemia - using EPODURE, a Biopump producing erythropoietin (EPO) 
- Hepatitis-C - using INFRADURE - a Biopump producing interferon-alpha (IFN-a) 
- Haemophilia - using a Biopump to produce clotting Factor VIII 
The Company's Phase I/II clinical trial using EPODURE to treat anaemia in 
patients with chronic kidney disease, has demonstrated proof of concept of the 
Biopump. Designed to produce and deliver a therapeutic dose of EPO steadily for 
six months or more, EPODURE Biopumps have already provided effectiveanaemia 
treatment in most of these patients for 6-12 months, even at the low 
administered dose. 
Medgenics intends to develop its innovative products and bring them to market 
via multiple strategic partnerships with major pharmaceutical and/or medical 
device companies. In addition to treatments for Anemia, Hepatitis-C, Hemophilia, 
Medgenics plans to develop and/or out-license a pipeline of future Biopump 
products targeting the large and rapidly growing global protein therapy market, 
which is forecast to reach US $87 billion by 2010. Other potential applications 
of Biopumps producing various proteins include multiple sclerosis, arthritis, 
pediatric growth hormone deficiency, obesity, and diabetes 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 IOEUGUBAPUPUUBR
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Medgenics(Regs) Charts.
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Medgenics(Regs) Charts.